<SEC-DOCUMENT>0000950170-24-076225.txt : 20240621
<SEC-HEADER>0000950170-24-076225.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621160543
ACCESSION NUMBER:		0000950170-24-076225
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240618
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MIGNONE ROBERTO
		CENTRAL INDEX KEY:			0001258394
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		241060175

	MAIL ADDRESS:	
		STREET 1:		C/O BRIDGER MANAGEMENT, LLC.
		STREET 2:		90 PARK AVENUE, 40TH FL.
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
		BUSINESS PHONE:		972 (3) 914-8213

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-18</periodOfReport>

    <issuer>
        <issuerCik>0000818686</issuerCik>
        <issuerName>TEVA PHARMACEUTICAL INDUSTRIES LTD</issuerName>
        <issuerTradingSymbol>TEVA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001258394</rptOwnerCik>
            <rptOwnerName>MIGNONE ROBERTO</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>124 DVORA HANEVI'A ST.,</rptOwnerStreet2>
            <rptOwnerCity>TEL AVIV</rptOwnerCity>
            <rptOwnerState>L3</rptOwnerState>
            <rptOwnerZipCode>6944020</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-06-18</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>519000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>17.03</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>981000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>[see footnote]</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>95683</value>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.16, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.</footnote>
        <footnote id="F3">The 981,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund, Ltd. (the &quot;Fund&quot;). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.</footnote>
        <footnote id="F4">The reported amount corrects an overstatement in the Form 4s filed on August 7, 2023 and June 17, 2024, which, after giving effect to the reported transactions, inadvertently duplicated the 1,500,000 indirectly held shares by also including such shares in the reporting person's direct holdings. The correct amount of shares directly owned after the reported transactions in such prior Form 4 filings should have been 74,575 shares and 95,683 shares, respectively.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Dov Bergwerk as attorney-in-fact for Roberto Mignone</signatureName>
        <signatureDate>2024-06-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
